Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04107298




Registration number
NCT04107298
Ethics application status
Date submitted
24/09/2019
Date registered
27/09/2019
Date last updated
14/02/2024

Titles & IDs
Public title
Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon
Scientific title
A Prospective, Multi-Center, Single-Arm, Feasibility Study to Assess the Safety and Performance WIth the SUNDANCE™ DruG Coated Balloon for the Treatment of De Novo or Restenotic Lesions in Infra-Popliteal Arteries
Secondary ID [1] 0 0
SUR19-002
Universal Trial Number (UTN)
Trial acronym
SWING
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease 0 0
Critical Lower Limb Ischemia 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - SUNDANCE™ Drug Coated Balloon

Experimental: SUNDANCE™ Drug Coated Balloon - SUNDANCE™ Drug Coated Balloon


Treatment: Devices: SUNDANCE™ Drug Coated Balloon
Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death
Timepoint [1] 0 0
30 Days
Primary outcome [2] 0 0
Primary Efficacy Endpoint: Rate of Late Lumen Loss (LLL)
Timepoint [2] 0 0
6 Months
Secondary outcome [1] 0 0
Rate of Device Success
Timepoint [1] 0 0
Acute/Periprocedural
Secondary outcome [2] 0 0
Rate of Technical Success
Timepoint [2] 0 0
Acute/Periprocedural
Secondary outcome [3] 0 0
Rate of Procedure Success
Timepoint [3] 0 0
Acute/Periprocedural
Secondary outcome [4] 0 0
Rate of Restenosis
Timepoint [4] 0 0
6 Months or prior
Secondary outcome [5] 0 0
Number of Participants with Primary Patency
Timepoint [5] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [6] 0 0
Major Adverse Event (MAE) rate
Timepoint [6] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [7] 0 0
Amputation Free Survival
Timepoint [7] 0 0
6 Months, 12 Months, 24 Months
Secondary outcome [8] 0 0
Hemodynamic outcomes
Timepoint [8] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [9] 0 0
Change in Rutherford-Becker Classification
Timepoint [9] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [10] 0 0
EQ-5D
Timepoint [10] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [11] 0 0
Walking Impairment Questionnaire (WIQ)
Timepoint [11] 0 0
30 Days, 6 Months, 12 Months, 24 Months
Secondary outcome [12] 0 0
Vascular Quality of Life Questionnaire (VascuQol)
Timepoint [12] 0 0
30 Days, 6 Months, 12 Months, 24 Months

Eligibility
Key inclusion criteria
Clinical Inclusion Criteria

* Subject is =18 years.
* Subject has target limb Rutherford classification 4 or 5. Rutherford classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (i.e., no more than 7 Rutherford class 3 subjects may be enrolled in the study).
* Subject has provided written informed consent and is willing to comply with study follow-up requirements.

Clinical
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Subject has acute limb ischemia.
* Subject underwent intervention involving the target vessel (not a proximal inflow vessel) within the previous 90 days.
* Subject previously underwent PTA of the target lesion vessel using a DCB or DES.
* Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure.
* Subjects with heel gangrene, deep heel ulcers, osteomyelitis of tarsal or metatarsal bones (which extends beyond the metatarsal head immediately adjacent to the metatarso-phalangeal joint), and subjects with exposed vital structures (e.g., medial or lateral malleolus).
* Subjects requiring pedal angioplasty.
* Subjects that are non-ambulatory and confined to bed.
* Women who are pregnant, breast-feeding or intend to become pregnant or men who intend to father children during the time of the study.
* Subject has history of Class 3 (and above) congestive heart failure (CHF) in past 6 months.
* Subject has life expectancy less than 12 months.
* Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
* Subject has known hypersensitivity to sirolimus
* Subject has a known contraindication to the intended concomitant medications.
* Subject is allergic to ALL antiplatelet treatments.
* Subject has impaired renal function (i.e. serum creatinine level =2.5 mg/dL or =221 µmol/L).
* Subject had major limb amputation on the affected side in last year or has planned major limb amputation.
* Subject is receiving immunosuppressant therapy.
* Subject has known or suspected active infection at the time of the index procedure.
* Subject has platelet count <100,000/mm3 or >700,000/mm3.
* Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure.
* Subject is diagnosed with coagulopathy or other disorders which are contraindications for treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
* Subject has history of stroke within the past 3 months.
* Subject has a history of myocardial infarction within the past 30 days.
* Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
* Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol.
* Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
* Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure.
* Subject had previous bypass surgery of the target lesion.
* Subject had previously implanted stent in target lesion.
* Subject had previous treatment of the target vessel with thrombolysis or surgery.
* Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.

Angiographic Inclusion Criteria

* The target lesion/vessel must meet all of the following angiographic criteria for the subject to participate in the trial:
* De novo lesion(s) or non-stented restenotic lesion
* Target lesion location starts at the P3 segment and terminates at 1cm above the ankle. Note: Isolated P3 lesion is not allowed. If a lesion starts in the P3 segment, it must continue into the infrapopliteal.
* Target vessel diameter =2 mm and =4 mm, based on visual estimation.
* Target lesion must have angiographic evidence of =70% stenosis by operator visual estimate.
* Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion. Use of re-entry/crossing devices is not allowed. Crossing may be performed retrograde, but treatment must be performed antegrade.

Uncomplicated: Upon visual inspection, no occurrence of embolization, perforation, or occurrence of flow-limiting dissection.

* Target lesion(s) must be =230 mm in total lesion(s) length by operator visual estimate. A maximum of two lesions may be treated. The two lesions may be in one infrapopliteal vessel or in two distinct infrapopliteal vessels. Note: Tandem lesions may be considered a single lesion if they are separated by =30 mm.
* After pre-dilatation, the target lesion has =70% residual stenosis, absence of a flow limiting dissection (Grade D or greater) and treatable with available device matrix.
* A patent inflow artery free from significant stenosis (=50% stenosis) as confirmed by angiography.
* At least one patent native outflow artery to the ankle or foot distal to the lesion being treated, free from significant stenosis (=50% stenosis) as confirmed by angiography.

Angiographic Exclusion Criteria

* Aneurysm in the target vessel or proximal inflow artery.
* Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length =15 cm.
* Significant stenosis (= 50%) in inflow lesion or occlusion in the ipsilateral iliac, SFA, popliteal arteries left untreated.
* Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, or re-entry devices.
* Significant target vessel tortuosity or other parameters prohibiting access to the target lesion.
* Presence of thrombus in the target vessel.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/06/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/01/2024
Sample size
Target
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [2] 0 0
Prince of Wales Private Hospital - Randwick
Recruitment hospital [3] 0 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 0 0
- Perth
Recruitment postcode(s) [2] 0 0
- Randwick
Recruitment postcode(s) [3] 0 0
- St Leonards
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Graz
Country [2] 0 0
Germany
State/province [2] 0 0
Bad Krozingen
Country [3] 0 0
Germany
State/province [3] 0 0
Sonneberg
Country [4] 0 0
Latvia
State/province [4] 0 0
Riga
Country [5] 0 0
New Zealand
State/province [5] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
SurModics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.
Trial website
https://clinicaltrials.gov/study/NCT04107298
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04107298